Gadolinium Exposure From MRI Not Linked to Parkinsonism

This article originally appeared here.
Share this content:
Gadolinium Exposure From MRI Not Linked to Parkinsonism
Gadolinium Exposure From MRI Not Linked to Parkinsonism

WEDNESDAY, July 6, 2016 (HealthDay News) -- Gadolinium exposure seems not to be associated with parkinsonism, according to a research letter published online July 5 in the Journal of the American Medical Association.

Blayne Welk, M.D., from Western University in London, Canada, and colleagues conducted a population-based study to examine the correlation between gadolinium exposure and parkinsonism. Patients older than 66 years who underwent an initial magnetic resonance imaging (MRI) exam between April 2003 and March 2013 were identified. The primary outcome, a new diagnosis of parkinsonism based on a validated definition, was evaluated in patients who were exposed to gadolinium-enhanced MRIs versus patients who received non-gadolinium-enhanced MRIs. Data were included for 246,557 patients undergoing at least one MRI, of whom 40.5 percent received at least one dose of gadolinium.

The researchers found that the most common initial non-gadolinium-enhanced MRI was of an extremity and that the most common gadolinium-enhanced MRI was of the abdomen (76 and 39.2 percent, respectively). Incident parkinsonism developed in 1.16 and 1.17 percent of unexposed patients and those exposed to gadolinium, respectively. In adjusted analysis, among patients with cumulative gadolinium exposure, there was no significantly increased risk of parkinsonism compared with those exposed to non-gadolinium-enhanced MRIs (hazard ratio, 1.04; 95 percent confidence interval, 0.98 to 1.09).

"This result does not support the hypothesis that gadolinium deposits in the globus pallidi lead to neuronal damage manifesting as parkinsonism," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »